去势抵抗性前列腺癌治疗后PSMA与FDG PET摄取变化
这项临床前研究在去势抵抗性前列腺癌小鼠移植瘤模型中,比较雄激素剥夺治疗(ADT)后多西他赛治疗过程中[18F]JK-PSMA-7与[18F]FDG PET/CT摄取变化,并与流式细胞术检测PSMA表达对照。结果显示ADT早期无影响;多西他赛后第12天前PSMA摄取显著高于FDG,提示PSMA表达持续;第26天起肿瘤快速生长时两者摄取均持续下降,但PSMA下降更快,PSMA阳性细胞比例同步降至非特异性水平。结论提示以PSMA显像监测CRPC治疗需谨慎,摄取降低可能与去分化及快速增殖肿瘤细胞PSMA表达下调有关。
要点
- ADT单独对LNCaP移植瘤无早期影响,肿瘤继续进展。
- 多西他赛后第12天前PSMA摄取显著高于FDG,PSMA表达持续。
- 第26天起肿瘤快速扩增,PSMA与FDG摄取均下降,PSMA降幅更快。
核心结论
- 以PSMA显像监测CRPC治疗需谨慎,摄取的降低可能与去分化及快速增殖肿瘤细胞PSMA表达下调有关。
研究设计与样本
- 临床前研究,去势并补充睾酮的小鼠移植人LNCaP去势抵抗性前列腺癌,先移除睾酮植入物行ADT,2周后单次注射多西他赛(400 μg/20-g mouse)。
- 在多西他赛前、ADT前及多西他赛后第12、26、47、69天行[18F]JK-PSMA-7 PET/CT,并与[18F]FDG PET/CT及流式细胞术检测肿瘤活检PSMA表达对照。
主要发现
- ADT单独对LNCaP肿瘤无早期影响,肿瘤继续进展。
- 多西他赛后第12天前[18F]JK-PSMA-7摄取显著高于[18F]FDG,提示这些时间点PSMA表达持续。
- 第26天起肿瘤快速扩增时,[18F]JK-PSMA-7与[18F]FDG摄取均持续下降,但PSMA摄取下降明显更快。
- 肿瘤活检中PSMA阳性细胞比例随时间类似下降,并在同一时间段后降至非特异性水平。
临床怎么用
- 对CRPC患者用PSMA显像做治疗监测时,摄取的降低不应直接等同于治疗有效,需结合肿瘤去分化与增殖状态解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This preclinical study aims to evaluate the extent to which a change in prostate-specific membrane antigen (PSMA) expression of castration-resistant prostate cancer (CRPC) following standard treatment is reflected in [18F]JK-PSMA-7 PET/CT. METHODS: Castrated mice supplemented with testosterone implant were xenografted with human LNCaP CRPC. After appropriate tumour growth, androgen deprivation therapy (ADT) was carried out by the removal of the implant followed by a single injection of docetaxel (400 μg/20-g mouse) 2 weeks later. [18F]JK-PSMA-7 PET/CT were performed before ADT, then before and at days 12, 26, 47 and 69 after docetaxel administration. The [18F]JK-PSMA-7 PET data were compared to corresponding unspecific metabolic [18F]FDG PET/CT and ex vivo quantification of PSMA expression estimated by flow cytometry on repeated tumour biopsies. RESULTS: ADT alone had no early effect on LNCaP tumours that pursued their progression. Until day 12 post-docetaxel, the [18F]JK-PSMA7 uptake was significantly higher than that of [18F]FDG, indicating the persistence of PSMA expression at those time points. From day 26 onwards when the tumours were rapidly expanding, both [18F]JK-PSMA7 and [18F]FDG uptake continuously decreased although the decrease in [18F]JK-PSMA uptake was markedly faster. The fraction of PSMA-positive cells in tumour biopsies decreased similarly over time to reach a non-specific level after the same time period. CONCLUSION: Applying PSMA-based imaging for therapy monitoring in patients with CRPC should be considered with caution since a reduction in [18F]JK-PSMA-7 PET uptake after successive ADT and chemotherapy may be related to downregulation of PSMA expression in dedifferentiated and rapidly proliferating tumour cells.
引用
- Van Simaeys G, Doumont G, De Maeseneire C, et al. [18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice. Eur J Nucl Med Mol Imaging. 2021. PMID: 33398412. doi:10.1007/s00259-020-05169-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。